Study on the compatibility stability of 16 commonly used intravenous antibiotics in ICU
- VernacularTitle:ICU常用16种静脉用抗菌药物配伍稳定性研究
- Author:
Liting ZHANG
1
;
Haotian YANG
2
;
Siqi YU
1
;
Liju FAN
1
;
Jing AN
1
Author Information
1. School of Pharmacy，Hebei Medical University，Shijiazhuang 050017，China;Dept. of Pharmacy，Hebei General Hospital，Shijiazhuang 050051，China
2. Dept. of Pharmacy，Hebei General Hospital，Shijiazhuang 050051，China;Hebei Provincial Key Laboratory of Clinical Pharmacy，Shijiazhuang 050051，China
- Publication Type:Journal Article
- Keywords:
antibiotics;
intravenous drugs;
compatibility stability;
compatibility;
intensive care unit
- From:
China Pharmacy
2026;37(4):468-475
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To systematically analyze the compatibility stability of commonly used intravenous antibiotics in the intensive care unit （ICU）， and to provide evidence-based support for rational clinical drug use. METHODS Medication data from the ICU of Hebei General Hospital between January and December 2024 were extracted from the Prescription Automatic Screening System. Commonly used intravenous antibiotics and other intravenous drugs in the ICU were selected through consultations with critical care and pharmacy experts in Hebei province， drug package inserts and compatibility information retrieved from Micromedex， Trissel’s Injectable Drug Handbook and PubMed. The physicochemical stability of drug combinations was analyzed. In addition， Cytoscape 3.10.2 software was used to construct a drug compatibility network for identifying high-risk drugs. RESULTS &CONCLUSIONS A total of 904 pairwise drug combinations involving 16 antibacterial agents and 65 intravenous drugs were collected. Among them， 549 combinations （60.7%） were compatible， 88 combinations （9.7%） were incompatible， 82 combinations （9.1%） had conflicting evidence， and 185 combinations （20.5%） lacked valid data support. High-risk combination drugs primarily involved Amphotericin B for injection， Ceftazidime for injection， Imipenem-cilastatin for injection， Ceftriaxone sodium for injection， Vancomycin hydrochloride for injection， etc. The main risk factors for drug-drug incompatibility included drug concentration， temperature， mixing rate， pH， and chemical structure. In clinical practice， drugs and diluents should be selected rationally based on specific compatibility data， and research and monitoring of drug compatibility should be further strengthened.
